Zafgen\'s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint

bluebird bio Announces First Patient Treated with bb2121 in CRB-401 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Neon Therapeutics Enters License Agreement with Sanquin for Peptide-MHC Assay Technology

Sage Therapeutics to Report Fourth Quarter and Full Year 2015 Financial Results on Wednesday, February 24, 2016

Blueprint Medicines to Present at RBC Capital Markets 2016 Global Healthcare Conference